Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Secondary Central Nervous System Lymphoma: early-phase trial registry
7 of 8 indexed Secondary Central Nervous System Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 7 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Secondary Central Nervous System Lymphoma: 8 US clinical trials tracked, 7 recruiting.
Secondary Central Nervous System Lymphoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition secondary-central-nervous-system-lymphoma
OPEN 7 | RECR 88% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Diseases (88% recruiting · 8 trials)
Secondary Central Nervous System Lymphoma lists 7 open slots (88% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Secondary Central Nervous System Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Secondary Central Nervous System Lymphoma is recruiting above its size-band peers.
7 of 8 indexed trials (87.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Secondary Central Nervous System Lymphoma research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Secondary Central Nervous System Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 26 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.
-
Secondary Central Nervous System Lymphoma research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05011045
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
James Rubenstein
NCT05351593
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
NCT07082868
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
NCT05256641
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
City of Hope Medical Center
NCT06922604
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
NCT05681195
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
NCT07137494
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
National Cancer Institute (NCI)
NCT03964090
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Secondary Central Nervous System Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Secondary Central Nervous System Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Secondary Central Nervous System Lymphoma page
8 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Secondary Central Nervous System Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Secondary Central Nervous System Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Secondary Central Nervous System Lymphoma condition card totals 8 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.